Novartis (India)

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Showing 10 of 173 papers

Research Article
10.1002/cpt.70239

Requirements for Phase Lag in First-In-Human Trials in India: Proceedings of a Panel Discussion.

Feb 11, 2026
Clinical pharmacology and therapeutics
Nusrat Shafiq + 10 more +10

India has strengthened its clinical research infrastructure and regulatory frameworks to support new drug development and early-phase clinical trials. However, historical concerns related to participant safety, ethics, and research capacity have limited the conduct of first-in-human (FIH) studies for products developed outside India. A multi-stakeholder panel comprising representatives from regulatory authorities, academia, industry, and funding agencies examined regulatory, ethical, infrastructural, and innovator perspectives relevant to conducting such FIH trials in India.

Research Article
10.1002/sscp.70192

Separation and Characterization of Degradation Impurities of Voxelotor by Liquid Chromatography and High Resolution Mass Spectrometry

Feb 01, 2026
SEPARATION SCIENCE PLUS
Srisailapu V S G B Prasad + 4 more +4

ABSTRACT Voxelotor is the first oxygen‐affinity modulator for hemoglobin. It was demonstrated that voxelotor could potentially modify the disease condition by raising hemoglobin levels and lowering hemolysis markers in sickle cell patients. The voxelotor was exposed to various kinds of degradation conditions, including hydrolysis, oxidation, and photolysis according to the conditions suggested by the International Council for Harmonization (ICH). Two voxelotor degradation impurities were detected during acid hydrolysis and oxidation (H 2 O 2 ). The in silico degradation profile was predicted using Zeneth. The degradation impurities were separated using ammonium formate (pH 6.5) and acetonitrile as the mobile phase with gradient elution and Phenomenex Gemini C18 column (250 × 4.6 mm, 5 µm) as a stationary phase. Liquid chromatography–high resolution mass spectrometry (LC‐HRMS) was used to characterize the separated degradation impurities. The structures of each degradation impurity were ascertained using the accurate masses acquired from LC‐HRMS/MS. A suitable mechanism for the formation of degradation impurities was proposed. The in silico studies for mutagenicity and toxicity were conducted using DEREK and SARAH Nexus.

Research Article
10.1016/j.jval.2025.09.541

EE157 Cost and Healthcare Resource Utilization Associated With Chronic Inducible Urticaria: A Targeted Literature Review

Dec 01, 2025
Value in Health
Mukhtar Ahmad Dar + 3 more +3

Research Article
10.1016/j.jval.2025.09.392

EE6 A Comparison of Treatment Costs for CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative HR+/HER2-: Early Breast Cancer (EBC) in Sweden

Dec 01, 2025
Value in Health
Aglaia Schiza + 8 more +8

Research Article
10.1016/j.jid.2025.10.089

085 Remibrutinib in patients with moderate to severe hidradenitis suppurativa: Patient reported outcomes from a randomized, phase 2, double-blind, placebo-controlled platform study

Dec 01, 2025
Journal of Investigative Dermatology
Ab Kimball + 6 more +6

Research Article
10.1016/j.jval.2025.09.2723

PCR250 Treatment Preferences in Adults With Chronic Spontaneous Urticaria Symptomatic on H1-Antihistamines in China: Insights From CHOICE-CSU 2 Study

Dec 01, 2025
Value in Health
Qiquan Chen + 6 more +6

Research Article
10.1182/blood-2025-4344

Interpretable deep learning predicts polycythemia vera and identifies novel genomic associations

Nov 03, 2025
Blood
Tejas Rao + 9 more +9

Research Article
10.1182/blood-2025-3202

Iptacopan monotherapy demonstrated improved clinical outcomes in a real-world cohort with paroxysmal nocturnal hemoglobinuria: Evidence from a managed access program

Nov 03, 2025
Blood
Silvia Sanz + 5 more +5

Research Article
2
10.1016/j.xphs.2025.103958

Understanding the degradation behavior of masitinib by Stress testing, UHPLC, HRMS, NMR, APCI-MS, DFT and prediction of toxicity using in silico tools.

Oct 01, 2025
Journal of pharmaceutical sciences
Vivek Dhiman + 4 more +4

Research Article
10.1016/s2152-2650(25)00780-3

POSTER: CML-1107 Asciminib Demonstrates Comparable Tolerability and Efficacy With Once-Daily (QD) and Twice-Daily (BID) Dosing in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Analysis (Week 72) of the Phase 3b AIM4CML Trial

Aug 28, 2025
Clinical Lymphoma Myeloma & Leukemia
Moshe Levy + 10 more +10